Merck Reports the US FDA Acceptance of sBLA for Keytruda (pembrolizumab) to Treat Advanced or Unresectable Biliary Tract Cancer
PharmaShots
JUNE 9, 2023
Shots: The US FDA has accepted an sBLA seeking approval of Keytruda + CT for LA unresectable or metastatic BTC. m-OS (12.7 vs 10.9mos.), 1 & 2 yr. OS rate (52% & 24.9%
Let's personalize your content